U.S. Markets closed

GW Pharmaceuticals announces agreement on Sativex in Germany

GW Pharmaceuticals announced that agreement for a revised mutually-acceptable reimbursement price for Sativex has been reached between Almirall S.A., GW's commercial partner in Germany, and the German National Association of Statutory Health Insurance Funds. This new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March 2013 which Almirall had considered to be unacceptable.